{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:58:38Z","timestamp":1777557518330,"version":"3.51.4"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Combination antiretroviral therapy (cART)-mediated immune reconstitution can establish a tumor-permissive microenvironment. In addition, compromised immune surveillance may contribute to more aggressive disease phenotypes in HIV patients; however, clinical evidence remains limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective analysis of clinical data of newly diagnosed Hodgkin lymphoma (HL) patients from 2014 to 2024 treated at four medical centers in China. The authors conducted clinical and immune function analysis of HIV-positive HL patients with special emphasis on prognosis and immune factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 19 patients were diagnosed as HIV positive. HIV-positive HL patients (HIV-HL) had more advanced stage disease, ECOG-PS, bulky disease, and B symptoms compared to HL patients without HIV (n=130). HIV-positive HL patients had decreased CD4 cell count, CD4\/CD8, and GZMB. Lower CD4 count was associated with more bulky disease and B symptoms and higher IL-2R and IL-6 levels in HIV-HL patients. And HIV-HL patients with bulky disease had less GZMB compared to non-bulky disease patients. The enrichment impact of gene alterations on bulky disease demonstrated that PI3K\/AKT, thyroid hormone signaling, NF\u2212kappa B signaling pathway, and EBV infection were involved. Immune dysfunction (CD4, CD8, and CD4\/CD8), on the other hand, showed no association with survival in both HIV-positive and negative HL patients. There were similar outcomes in patients with and without HIV treated by ABVD chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>HIV-associated Hodgkin lymphoma (HIV-HL) often presents with more aggressive clinical features, although outcomes are similar to those observed in HIV-negative HL patients. Impaired immune function may contribute to an increased tumor burden through multiple mechanisms. However, it was not associated with outcomes. HL treatment approaches might not necessarily require adjustment solely due to HIV status, but additional clinical evidence is needed to support this assertion.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1628909","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T11:03:46Z","timestamp":1756897426000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Advanced aggressive clinical features may be associated with immune dysfunction in patients with HIV-positive Hodgkin lymphoma in the cART era: a multicenter study from China"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiping","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifeng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenwen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishnu Prasad","family":"Adhikari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2011.396","article-title":"Proportions of kaposi sarcoma, selected non-hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS","volume":"305","author":"Shiels","year":"2011","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30118-1","article-title":"Epidemiology of haematological Malignancies in people living with HIV","volume":"7","author":"Kimani","year":"2020","journal-title":"Lancet HIV"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1016","article-title":"Deaths attributable to cancer in the US human immunodeficiency virus population during 2001-2015","volume":"72","author":"Horner","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"4366","DOI":"10.3390\/cancers13174366","article-title":"Hodgkin lymphoma in people living with HIV","volume":"13","author":"Navarro","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"ftv044","DOI":"10.1093\/femspd\/ftv044","article-title":"HIV-associated lymphoma in the era of combination antiretroviral therapy: Shifting the immunological landscape","volume":"73","author":"Carroll","year":"2015","journal-title":"Pathog Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e3283560697","article-title":"Impact of highly effective antiretroviral therapy on the risk for Hodgkin lymphoma among people with human immunodeficiency virus infection","volume":"24","author":"Goedert","year":"2012","journal-title":"Curr Opin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"507257","DOI":"10.1155\/2012\/507257","article-title":"HIV-associated Hodgkin\u2019s lymphoma: Prognosis and therapy in the era of cART","volume":"2012","author":"Jacobson","year":"2012","journal-title":"Adv Hematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30473","article-title":"The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis","volume":"140","author":"Carbone","year":"2017","journal-title":"Int J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200301030-00011","article-title":"Improved survival in HIV-related Hodgkin \u2018s lymphoma since the introduction of highly active antiretroviral therapy","volume":"17","author":"Gerard","year":"2003","journal-title":"AIDS"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1182\/blood.V124.21.2954.2954","article-title":"Characteristics and outcome of HIV associated classical Hodgkin\u2019s lymphoma among 68 patients included in the French ANRS CO16 lymphovir cohort study","volume":"124","author":"Besson","year":"2014","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/GO.21.00163","article-title":"HIV and hodgkin lymphoma survival: A prospective study in Botswana","volume":"8","author":"Moahi","year":"2022","journal-title":"JCO Glob Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000382","article-title":"Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort","volume":"28","author":"Hleyhel","year":"2014","journal-title":"AIDS"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003904","article-title":"Association between obesity and cancer risk in adults with HIV in Korea","volume":"38","author":"Kim","year":"2024","journal-title":"AIDS"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2217\/bmm.15.13","article-title":"The role of the tumor microenvironment in HIV-associated lymphomas","volume":"9","author":"Taylor","year":"2015","journal-title":"biomark Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/1545109711431492","article-title":"Characterization of HIV-associated Hodgkin\u2019s lymphoma in HIV-infected patients: a single-center experience","volume":"11","author":"Ruiz","year":"2012","journal-title":"J Int Assoc Physicians AIDS Care (Chic)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.4193","article-title":"HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era","volume":"30","author":"Montoto","year":"2012","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000030765","article-title":"Impact of the HIV infection in Hodgkin lymphoma individuals: A protocol for systematic review and meta-analysis","volume":"101","author":"Fagundes","year":"2022","journal-title":"Med (Baltimore)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-301531","article-title":"HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T-cell lymphocytes","volume":"117","author":"Bohlius","year":"2011","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-498964","article-title":"Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients","volume":"122","author":"Barta","year":"2013","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2018.09.002","article-title":"IL-6: a cytokine at the crossroads of autoimmunity","volume":"55","author":"Jones","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-230X(02)84008-8","article-title":"Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer","volume":"84","author":"Dalgleish","year":"2002","journal-title":"Adv Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243386","article-title":"Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin\u2019s lymphoma","volume":"106","author":"Sparano","year":"2021","journal-title":"Haematologica"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01850","article-title":"A natural impact: NK cells at the intersection of cancer and HIV disease","volume":"10","author":"Lucar","year":"2019","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1042\/BST20220244","article-title":"Protective HLA-B57: T cell and natural killer cell recognition in HIV infection","volume":"50","author":"Lobos","year":"2022","journal-title":"Biochem Soc Trans"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1137","article-title":"CD4\/CD8 ratio and the risk of kaposi sarcoma or non-hodgkin lymphoma in the context of efficiently treated human immunodeficiency virus (HIV) infection: A collaborative analysis of 20 european cohort studies","volume":"73","author":"Caby","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-024109","article-title":"Hodgkin lymphoma and immunodeficiency in persons with HIV\/AIDS","volume":"108","author":"Biggar","year":"2006","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1935851","article-title":"Immunodeficiency-associated hodgkin lymphoma","volume":"14","author":"Carbone","year":"2021","journal-title":"Expert Rev Hematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1628909\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T11:03:47Z","timestamp":1756897427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1628909\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2025.1628909"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1628909","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]},"article-number":"1628909"}}